



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



CRIM1 siRNA (m): sc-142569

BACKGROUND

CRIM1 (cysteine-rich motor neuron 1) is a glycosylated type I transmembrane protein expressed in pericytes surrounding the arterial vasculature, podocytes, parietal cells, and mesangial cells of the glomerulus and in the developing spinal cord. It consists of six chordin-like cysteine-rich repeats (CRRs) and an N-terminal Insulin-like growth factor binding protein-like motif. The CRRs are contained in the extracellular domain which can be cleaved and released as a secreted ectodomain from the cell membrane. CRIM1 may be involved in the regulation of BMP signaling activity in kidney as well as various other tissues. CRIM1 interacts with BMP4 and BMP7 via the CRRs and functions as an antagonist. This interaction leads to the tethering of pre-BMP to the cell surface and reduced production, processing and secretion of mature BMP. In addition, CRIM1 may also play a role in capillary formation and maintenance during angiogenesis.

REFERENCES

1. Kolle, G., Georgas, K., Holmes, G.P., Little, M.H. and Yamada, T. 2000. CRIM1, a novel gene encoding a cysteine-rich repeat protein, is developmentally regulated and implicated in vertebrate CNS development and organogenesis. *Mech. Dev.* 90: 181-193.
2. Georgas, K., Bowles, J., Yamada, T., Koopman, P. and Little, M.H. 2000. Characterisation of Crim1 expression in the developing mouse urogenital tract reveals a sexually dimorphic gonadal expression pattern. *Dev. Dyn.* 219: 582-587.
3. Kolle, G., Jansen, A., Yamada, T. and Little, M. 2002. In ovo electroporation of Crim1 in the developing chick spinal cord. *Dev. Dyn.* 226: 107-111.
4. Glienke, J., Sturz, A., Menrad, A. and Thierach, K.H. 2002. CRIM1 is involved in endothelial cell capillary formation *in vitro* and is expressed in blood vessels *in vivo*. *Mech. Dev.* 119: 165-175.
5. Wilkinson, L., Kolle, G., Wen, D., Piper, M., Scott, J. and Little, M. 2003. CRIM1 regulates the rate of processing and delivery of bone morphogenetic proteins to the cell surface. *J. Biol. Chem.* 278: 34181-34188.
6. Liu, F., Lei, W., O'Rourke, J.P. and Ness, S.A. 2006. Oncogenic mutations cause dramatic, qualitative changes in the transcriptional activity of c-Myb. *Oncogene* 25: 795-805.
7. Sun, J., Zhuang, F.F., Mullersman, J.E., Chen, H., Robertson, E.J., Warburton, D., Liu, Y.H. and Shi, W. 2006. BMP4 activation and secretion are negatively regulated by an intracellular gremlin-BMP4 interaction. *J. Biol. Chem.* 281: 29349-29356.
8. Wilkinson, L., Gilbert, T., Kinna, G., Ruta, L.A., Pennisi, D., Kett, M. and Little, M.H. 2007. Crim1KST264/KST264 mice implicate Crim1 in the regulation of vascular endothelial growth factor-A activity during glomerular vascular development. *J. Am. Soc. Nephrol.* 18: 1697-1708.
9. Pennisi, D.J., Wilkinson, L., Kolle, G., Sohaskey, M.L., Gillinder, K., Piper, M.J., McAvoy, J.W., Lovicu, F.J. and Little, M.H. 2007. Crim1KST264/KST264 mice display a disruption of the Crim1 gene resulting in perinatal lethality with defects in multiple organ systems. *Dev. Dyn.* 236: 502-511.

CHROMOSOMAL LOCATION

Genetic locus: Crim1 (mouse) mapping to 17 E2.

PRODUCT

CRIM1 siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see CRIM1 shRNA Plasmid (m): sc-142569-SH and CRIM1 shRNA (m) Lentiviral Particles: sc-142569-V as alternate gene silencing products.

For independent verification of CRIM1 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-142569A, sc-142569B and sc-142569C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

CRIM1 siRNA (m) is recommended for the inhibition of CRIM1 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor CRIM1 gene expression knockdown using RT-PCR Primer: CRIM1 (m)-PR: sc-142569-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.